Search results
Results from the WOW.Com Content Network
BMB-202 is under development by Bright Minds Biosciences. [ 1 ] [ 2 ] As of April 2023, it is in preclinical research for depressive disorders and PTSD. [ 1 ] [ 2 ] The chemical structure of BMB-202 does not yet appear to have been disclosed, [ 1 ] [ 2 ] but it seems that it may be a phenethylamine . [ 5 ]
Bright Minds Biosciences (OTC: BMBIF), a Canadian-based biotechnology company, is developing the next-generation serotonergic drugs to treat various central nervous system (CNS) disorders. Over ...
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial ...
Emergent BioSolutions (NYSE: EBS) saw its shares tumble on Tuesday, due to news of a share sell-off. The selling parties are mainly entities affiliated with OHA Agency, a business that provided a ...
Click here for the latest stock market news and in-depth analysis, including events that move stocks. Read the latest financial and business news from Yahoo Finance. Show comments.
BMB-201 is under development by Bright Minds Biosciences. [ 1 ] [ 2 ] As of October 2024, its highest developmental phase is preclinical research . [ 1 ] [ 2 ] The chemical structure of BMB-201 does not yet appear to have been disclosed.
α-Alkyltryptamines are a group of substituted tryptamines which possess an alkyl group, such as a methyl or ethyl group, attached at the alpha carbon, and in most cases no substitution on the amine nitrogen.
Capital One is working to resolve a technical issue that had thousands of customers reporting problems with direct deposits on Thursday. More than 2,000 people had reported issues with Capital One ...